| Literature DB >> 26571465 |
Aidan Hollis1, Paul Grootendorst2.
Abstract
Alberta, quickly followed by other Canadian provinces, has introduced a new pricing model for generic drugs, in which prices are inversely related to the number of generic manufacturers of the drug. This paper examines the rationale for the new policy.Mesh：
Substances：
Year: 2015 PMID： 26571465 PMCID： PMC4748362
Source DB: PubMed Journal: Healthc Policy ISSN： 1715-6572